Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Opthea Ltd

Healthcare AU OPT

0.6AUD
-(-%)

Last update at 2025-06-19T00:00:00Z

Day Range

0.600.60
LowHigh

52 Week Range

0.341.17
LowHigh

Fundamentals

  • Previous Close 0.60
  • Market Cap738.75M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-183.20056M
  • Revenue TTM0.21M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.21M
  • Diluted EPS TTM-0.43

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -148.44744M -99.11666M -50.28334M -17.22088M -24.89497M
Minority interest - - - - -
Net income -142.52108M -92.81737M -45.34450M -11.35760M -14.64413M
Selling general administrative 27.84M 17.83M 13.72M 4.00M 3.07M
Selling and marketing expenses - - - - 0.29M
Gross profit 0.11M 0.09M 0.07M -0.45620M -0.11488M
Reconciled depreciation 0.10M 0.08M 0.11M 0.14M 0.03M
Ebit -146.79830M -93.72380M -28.62855M -17.20638M -25.98888M
Ebitda -146.69707M -93.64542M -28.52189M -17.10742M -25.96570M
Depreciation and amortization 0.10M 0.08M 0.11M 0.10M 0.02M
Non operating income net other - - - - -
Operating income -146.79830M -93.72380M -28.62855M -17.20638M -25.98888M
Other operating expenses 150.13M 96.63M 39.71M 17.48M 25.73M
Interest expense 13.46M 0.24M 21.65M 0.01M 1.09M
Tax provision -5.92635M -6.29929M -4.93885M -8.53312M -14.63697M
Interest income 1.58M 0.24M 0.37M 0.32M 1.12M
Net interest income -10.23466M 0.24M 0.37M 0.72M 0.76M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.92635M -6.29929M -4.93885M -5.86328M -10.25084M
Total revenue 0.11M 0.09M 0.07M 0.09M 0.16M
Total operating expenses 150.13M 96.63M 39.71M 17.48M 25.73M
Cost of revenue 0.17M 0.16M 0.43M 0.54M 0.27M
Total other income expense net 11.81M -5.39286M -21.65479M -0.01449M 1.09M
Discontinued operations - - - - -
Net income from continuing ops -142.52108M -92.81737M -45.34450M -16.52928M -20.91006M
Net income applicable to common shares -142.52109M -92.81737M -45.34450M -16.52928M -20.91006M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 188.79M 98.64M 60.05M 138.41M 49.40M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - 8.72M 14.39M 6.19M
Total liab 264.60M 104.40M 12.07M 3.12M 4.86M
Total stockholder equity -75.81008M -5.75855M 47.98M 135.29M 44.53M
Deferred long term liab - - - - -
Other current liab 24.84M 0.75M 0.64M 0.58M 0.16M
Common stock 466.08M 320.88M 235.28M 234.15M 111.38M
Capital stock 466.08M 320.88M 235.28M 234.15M 111.38M
Retained earnings -579.70454M -359.36781M -216.94135M -124.12398M -70.49118M
Other liab - 0.00763M 0.03M 0.02M 0.04M
Good will - - - - -
Other assets - 0.05M 0.11M 0.17M 0.00000M
Cash 172.47M 89.19M 44.63M 118.19M 42.62M
Cash and equivalents - 77.12M 32.78M 102.65M 40.57M
Total current liabilities 64.06M 18.65M 12.04M 3.11M 4.75M
Current deferred revenue 1.06M - - - 0.48M
Net debt -30.82366M -89.00700M -44.63129M -118.08021M -42.43330M
Short term debt 0.09M 0.10M 0.00000M 0.11M 0.10M
Short long term debt - - - - -
Short long term debt total 141.65M 0.18M - 0.11M 0.18M
Other stockholder equity - 20.09M 29.64M 25.26M 9.50M
Property plant equipment - 0.20M 0.03M 0.12M 0.28M
Total current assets 188.19M 98.39M 59.91M 138.12M 49.00M
Long term investments - - - 0.00000M 0.29M
Net tangible assets - -5.85318M 47.98M 135.29M 64.81M
Short term investments - - - - -
Net receivables 11.82M 6.56M 6.56M 5.54M 0.20M
Long term debt 141.55M 85.66M - - -
Inventory - - - - -
Accounts payable 38.06M 17.80M 11.40M 2.42M 4.01M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 37.81M 32.73M 29.64M 25.26M 3.64M
Additional paid in capital - - - - -
Common stock total equity - - - - 162.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.47M 0.05M 0.11M 0.17M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.60M 0.26M 0.14M 0.29M 0.39M
Capital lease obligations 0.09M 0.18M 0.00000M 0.11M 0.27M
Long term debt total - 85.74M 0.00000M 0.00000M 0.12M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.02195M -0.01691M 0.67M 0.48M 0.34M
Change to liabilities 7.30M 8.51M -1.55244M -0.05691M -1.42798M
Total cashflows from investing activities -0.02195M -0.01691M 0.66M 0.48M 0.32M
Net borrowings 84.43M -0.08558M -0.08737M -0.10019M -0.10019M
Total cash from financing activities 248.70M 0.24M 156.76M 48.98M 12.63M
Change to operating activities 6.28M 5.85M -14.19104M 0.06M -0.06685M
Net income -211.88068M -127.99021M -60.78802M -16.52928M -20.91006M
Change in cash 69.08M -92.52939M 95.41M 40.49M -10.97531M
Begin period cash flow 64.90M 157.43M 62.02M 21.53M 32.51M
End period cash flow 133.99M 64.90M 157.43M 62.02M 21.53M
Total cash from operating activities -179.30389M -98.36710M -61.05838M -8.78227M -24.18516M
Issuance of capital stock 81.82M 0.00000M 105.48M 33.72M 8.85M
Depreciation 0.15M 0.11M 0.14M 0.14M 0.03M
Other cashflows from investing activities - 0.00000M 0.67M 0.48M 0.34M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.56M 0.42M -0.49563M 0.01M 0.10M
Sale purchase of stock 167.36M 0.26M 117.02M 49.08M 12.63M
Other cashflows from financing activities -0.03454M -0.03243M -0.02976M -0.03341M 12.63M
Change to netincome 7.86M 6.74M 15.80M 7.58M -1.91131M
Capital expenditures 0.03M 0.02M 0.02M 0.00724M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 20.75M 20.22M -21.60105M 0.02M -1.39688M
Stock based compensation 5.83M 5.25M 3.90M 0.73M 0.97M
Other non cash items 11.77M 10.34M 22.23M 12.56M -1.91131M
Free cash flow -179.33653M -98.39042M -61.07541M -8.78951M -24.20323M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OPT
Opthea Ltd		 - -% 0.60 - 6.75 3537.08 4.21 5781.33 -1.0623
CSL
CSL Ltd		 1.50 0.63% 240.21 28.64 32.15 7.65 4.04 5.81 18.03
TLX
Telix Pharmaceuticals Ltd		 -0.08 0.32% 24.92 166.67 57.47 10.68 14.73 10.52 89.03
MSB
Mesoblast Ltd		 -0.03 1.80% 1.64 - 454.55 367.78 2.98 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.10 0.80% 12.54 11.61 75.76 7.37 4.49 6.61 8.03

Reports Covered

Stock Research & News

View All

Profile

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.

Opthea Ltd

650 Chapel Street, South Yarra, VIC, Australia, 3141

Key Executives

Name Title Year Born
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. MD, CEO & Exec. Director 1974
Ms. Judith J. Robertson B.A., M.B.A. Chief Commercial Officer 1960
Dr. Joel Naor M.D., MBA, MSc Chief Medical Officer NA
Ms. Karen Adams CPA VP of Fin. & Company Sec. 1971
Mr. Timothy E. Morris CPA, CPA Chief Financial Officer 1961
Ms. Annie Lee Fin. & Operations Mang. NA
Dr. Michael Gerometta Ph.D. Head of Chemistry, Manufacturing & Controls Devel. 1964
Mr. Bruno Gagnon BPHARM, M.Sc. Sr. VP of Global Clinical Operations NA
Dr. Ian Leitch Director of Clinical Research 1963
Dr. James Goding Independent Consultant NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.